|
WARS2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.31559999455777E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.39879999700088E-08 |
| Normal-vs-Stage2 |
2.640200E-03 |
| Normal-vs-Stage3 |
1.24260000000653E-06 |
| Normal-vs-Stage4 |
4.019800E-04 |
| Stage1-vs-Stage2 |
1.527640E-01 |
| Stage1-vs-Stage3 |
9.735400E-01 |
| Stage1-vs-Stage4 |
3.151000E-01 |
| Stage2-vs-Stage3 |
1.930980E-01 |
| Stage2-vs-Stage4 |
6.948400E-01 |
| Stage3-vs-Stage4 |
3.515800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.39839994718028E-09 |
| Normal-vs-AfricanAmerican |
4.063800E-01 |
| Normal-vs-Asian |
2.23469999999226E-05 |
| Caucasian-vs-AfricanAmerican |
2.038700E-03 |
| Caucasian-vs-Asian |
7.205000E-01 |
| AfricanAmerican-vs-Asian |
6.644200E-03 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.10009999998439E-07 |
| Normal-vs-Female |
2.21560000013277E-07 |
| Male-vs-Female |
5.477800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.25700000303186E-08 |
| Normal-vs-Age(41-60Yrs) |
1.24810000001752E-06 |
| Normal-vs-Age(61-80Yrs) |
3.71610000000633E-05 |
| Normal-vs-Age(81-100Yrs) |
1.041620E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.041800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.057850E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.996600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.793600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.213000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.860800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.099200E-01 |
| Classical-VS-Follicular |
3.821600E-01 |
| Classical-VS-Other |
9.173400E-01 |
| Classical-VS-Normal |
9.08160002754954E-09 |
| Tall-VS-Follicular |
7.556400E-01 |
| Tall-VS-Other |
9.783400E-01 |
| Tall-VS-Normal |
1.362220E-03 |
| Follicular-VS-Other |
8.761400E-01 |
| Follicular-VS-Normal |
1.598350E-03 |
| Other-VS-Normal |
7.950100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2497000001499E-07 |
| Normal-vs-N1 |
1.29610000509928E-08 |
| N0-vs-N1 |
3.753800E-02 |
|
|
